RT Journal Article
SR Electronic
T1 A scalable variational approach to characterize pleiotropic components across thousands of human diseases and complex traits using GWAS summary statistics
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.03.27.23287801
DO 10.1101/2023.03.27.23287801
A1 Zhang, Zixuan
A1 Jung, Junghyun
A1 Kim, Artem
A1 Suboc, Noah
A1 Gazal, Steven
A1 Mancuso, Nicholas
YR 2023
UL http://medrxiv.org/content/early/2023/03/29/2023.03.27.23287801.abstract
AB Genome-wide association studies (GWAS) across thousands of traits have revealed the pervasive pleiotropy of trait-associated genetic variants. While methods have been proposed to characterize pleiotropic components across groups of phenotypes, scaling these approaches to ultra large-scale biobanks has been challenging. Here, we propose FactorGo, a scalable variational factor analysis model to identify and characterize pleiotropic components using biobank GWAS summary data. In extensive simulations, we observe that FactorGo outperforms the state-of-the-art (model-free) approach tSVD in capturing latent pleiotropic factors across phenotypes, while maintaining a similar computational cost. We apply FactorGo to estimate 100 latent pleiotropic factors from GWAS summary data of 2,483 phenotypes measured in European-ancestry Pan-UK BioBank individuals (N=420,531). Next, we find that factors from FactorGo are more enriched with relevant tissue-specific annotations than those identified by tSVD (P=2.58E-10), and validate our approach by recapitulating brain-specific enrichment for BMI and the height-related connection between reproductive system and muscular-skeletal growth. Finally, our analyses suggest novel shared etiologies between rheumatoid arthritis and periodontal condition, in addition to alkaline phosphatase as a candidate prognostic biomarker for prostate cancer. Overall, FactorGo improves our biological understanding of shared etiologies across thousands of GWAS.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded in part by the National Institutes of Health (NIH) under awards P01CA196569, R01HG012133, R01CA258808, R35GM147789 and R00HG010160.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThis study relied on publicly available summary statistics. All results produced in this work are available online at zenodo: https://doi.org/10.5281/zenodo.7765048 https://doi.org/10.5281/zenodo.7765048 https://pan.ukbb.broadinstitute.org/